The company reported GAAP revenue of $2.60 billion for Q3 2024, up 5%; GAAP diluted EPS of $1.24, compared with $1.39 a year earlier; and adjusted EPS of $3.08, up 12%. GAAP operating margin was 18.3%, compared with 22.5% a year earlier.

1. 01

   The company reported GAAP revenue of $2.60 billion for Q3 2024, up 5%; GAAP diluted EPS of $1.24, compared with $1.39 a year earlier; and adjusted EPS of $3.08, up 12%. GAAP operating margin was 18.3%, compared with 22.5% a year earlier.

2. 02

   The company said it signed a Purchase Agreement to sell AdvancedMD, Inc. to an affiliate of Francisco Partners Management, L.P. for a total purchase price of $1.125 billion. It expects the sale to close in Q4 2024, subject to regulatory approvals and other customary closing conditions.

3. 03

   The company said it entered into an accelerated share repurchase (ASR) of $600 million as part of its previously approved share repurchase program. About five million shares are to be received on October 31, 2024, and final settlement of the ASR is expected by December 31.

4. 04

   The company said it maintained its 2024 outlook for adjusted net revenue of $9.17 billion to $9.30 billion, reflecting growth of 6% to 7%, and adjusted EPS of $11.54 to $11.70, reflecting growth of 11% to 12%. It said annual adjusted operating margin is expected to expand by up to 50 basis points.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.